BioCentury | Oct 27, 2017
Company News

NIH, Geom to conduct Phase I of GT-1

NIH's National Institute of Allergy and Infectious Diseases (NIAID) and Geom Therapeutics Inc. (San Diego, Calif.) partnered to conduct a Phase I trial of Geom's lead candidate GT-1 (LCB10-0200). The double-blind, placebo-controlled, dose-escalation study will...
BioCentury | Jun 9, 2016

Sanofi's post-reconstruction era

Lauren Martz, Senior Writer Five years after taking the helm as Sanofi 's president of global R&D, Elias Zerhouni is rounding out his strategy to revamp the division and rebuild the pipeline with the appointment...
BioCentury | Mar 21, 2016
Product Development

Korea rising

The Korean biopharma industry is mainly known for biosimilars and me-too products. But a cohort of innovator biotechs in Korea is coming of age, bolstered by an infusion of cash from the government and by...
BioCentury | Dec 5, 2011
Product Development

Change-up for BATTER-UP

...predicted response to anti-TNF therapy with 89% accuracy. The genes include clathrin light chain ( Lcb...
Items per page:
1 - 4 of 4